Catalent And Toyobo Team Up To Launch GPEx®




Catalent and Toyobo team up to launch GPEx® in Japan

Published in:   Outsourcing-pharma.com by Natalie Morrison

Published date: 09/21/11

Summary: Catalent has struck up a deal with Toyobo Biologics to launch its cell line engineering technology on the Japanese market. Under the agreement, Catalent will use the platform, known as GPEx®, for the manufacturing of mammalian cells while Japanese company Toyobo will provide local clinical and commercial manufacturing capabilities.

Click here to read the entire article